Cytokeratin 13 Antibody (Ks13.1): sc-101460

Cytokeratin 13 Antibody (Ks13.1) is a mouse monoclonal IgG1 antibody that detects Cytokeratin 13 (CK13) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). CK13 is a crucial component of the intermediate filament family, forming a heterotetramer with two type I acidic and two type II basic keratins, and typically associates with Cytokeratin 4. Anti-CK13 antibody (Ks13.1) recognizes proteins predominantly located in the cytoskeletal region of noncornified stratified squamous epithelia, where CK13 plays a vital role in maintaining cellular integrity and structural support. CK13 expression is particularly significant in squamous cell carcinomas, serving as a marker for tissue differentiation and aiding in malignant tumor characterization. Additionally, defects in the KRT13 gene, which encodes CK13, are linked to white sponge nevus of Cannon, a rare autosomal dominant disorder characterized by soft, white, spongy plaques in the oral mucosa. CK13 monoclonal antibody (Ks13.1) serves as an essential tool for researchers studying epithelial tissue dynamics, cancer biology, and genetic disorders associated with keratin mutations.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cytokeratin 13 Antibody (Ks13.1) References:

1. Stage-specific expression of the intermediate filament protein cytokeratin 13 in luminal epithelial cells of secretory phase human endometrium and peri-implantation stage rabbit endometrium.  |  Olson, GE., et al. 2002. Biol Reprod. 66: 1006-15. PMID: 11906920
2. Chromosomal mapping of human cytokeratin 13 gene (KRT13).  |  Romano, V., et al. 1992. Genomics. 14: 495-7. PMID: 1385306
3. In situ adenocarcinoma and squamous carcinoma of uterine cervix. Pathological and immunohistochemical analysis with cytokeratin 13.  |  Raspollini, MR., et al. 2007. Eur J Obstet Gynecol Reprod Biol. 134: 249-53. PMID: 16949723
4. Loss of cytokeratin 13 expression in squamous cell carcinoma of the tongue is a possible sign for local recurrence.  |  Yanagawa, T., et al. 2007. J Exp Clin Cancer Res. 26: 215-20. PMID: 17725101
5. Histopathological evaluation including cytokeratin 13 and Ki-67 in the border between Lugol-stained and -unstained areas.  |  Ohta, K., et al. 2010. Oncol Rep. 24: 9-14. PMID: 20514438
6. Evaluation of superficial oral squamous cell malignancy based on morphometry and immunoexpression of cytokeratin 13 and cytokeratin 17.  |  Yamashina, M., et al. 2014. Acta Cytol. 58: 67-75. PMID: 24247036
7. Synthesis of cytokeratin 13, a component characteristic of internal stratified epithelia, is not induced in human epidermal tumors.  |  Kuruc, N., et al. 1989. Differentiation. 42: 111-23. PMID: 2483837
8. Expression of Cytokeratin 13, 14, 17, and 19 in 4-nitroquinoline-1-oxide-induced Oral Carcinogenesis in Rat.  |  Saitoh, T., et al. 2016. Bull Tokyo Dent Coll. 57: 241-251. PMID: 28049972
9. Proteomic profiles and cytokeratin 13 as a potential biomarker of Ovis aries papillomavirus 3-positive and negative cutaneous squamous cell carcinomas.  |  Vitiello, V., et al. 2021. Res Vet Sci. 134: 112-119. PMID: 33360571
10. Coordinate control of growth and cytokeratin 13 expression by retinoic acid.  |  Kim, SY., et al. 1996. Mol Carcinog. 16: 6-11. PMID: 8634095

The preferred Cytokeratin 13 antibody is Cytokeratin 13 Antibody (A-5): sc-376901.